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Psychiatric drugs: reconsidering their mode of action and the 
implications for service user involvement 
Abstract
Purpose: The purpose of this paper is to examine two competing pharmacological 
models that have been used to understand how psychiatric drugs work: the 
disease-centred model and the drug-centred model. In addition, it explores the 
implications of these two models for mental health service users and the degree to which 
they are meaningfully involved in decisions about the use of psychiatric drugs.  
Design/methodology/approach: The approach is a conceptual review and critical 
comparison of two pharmacological models used to understand the mode of action of 
psychiatric drugs. On the basis of this analysis, the paper also provides a critical 
examination, supported by the available literature, of the implications of these two 
models for service user involvement in mental health care.   
Findings: The disease-centred model is associated with a tendency to view the use of 
psychiatric drugs as a technical matter that is to be determined by mental health 
professionals. In contrast, the drug-centred model emphasises the centrality of the 
individual experience of taking a psychiatric drug and implies a more equitable 
relationship between practitioners and mental health service users. 
Originality/value: Although infrequently articulated, assumptions about how psychiatric 
drugs work have important consequences for service user involvement in mental health 
care. Critical consideration of these assumptions is an important aspect of seeking to 
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maximise service user involvement in decisions about the use of psychiatric drugs as a 
response to their experience of mental distress.  
Introduction
A widespread and enduring notion about psychiatric drugs is that they work by targeting 
and correcting various biological dysfunctions that supposedly underlie the emergence 
and maintenance of mental distress. Despite its pervasiveness, this understanding of how 
psychiatric drugs work is increasingly being contested by those who work within and 
those who use mental health services (Moncrieff, 2008; Lacasse and Leo, 2015; Whitaker, 
2015; Roberts, 2018). Such a reconsideration of the mode of action of psychiatric drugs 
has important implications for the way in which they are used, the manner in which their 
potential benefits are balanced against their adverse effects and the extent to which those 
who use psychiatric drugs are meaningfully involved in decisions about their use. In 
seeking to explore these implications this paper will begin by critically examining the 
popular notion that psychiatric drugs work by selectively acting upon some form of 
biological dysfunction or chemical imbalance of which mental distress is a supposed 
manifestation. However, in contrast to this notion, it will move on to discuss an 
alternative understanding of psychiatric drugs as powerful psychoactive substances that, 
by acting upon the central nervous system in a non-specific rather than a targeted way, 
produce a range of physiological and psychological effects. Finally, this paper will 
consider critically the implications of these two ways of understanding how psychiatric 
drugs work for those who use mental health services and for the degree to which service 
users are meaningfully involved in decisions about the use of those drugs as a response to 
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the experience of mental distress.  
The disease-centred model of psychiatric drugs
A popular conception of psychiatric drugs is that they act upon the biological 
dysfunctions and disease processes that are commonly thought to underlie the emergence 
and maintenance of mental distress. This explanation of psychiatric drugs draws upon a 
dominant pharmacological model, what Moncrieff (2015) has referred as ‘the 
disease-centred model’, that is used to explain how drugs in other fields of medicine are 
understood as acting upon the biological causes of a disease or the biological processes 
that produce the symptoms associated with a particular disease. In explaining how 
psychiatric drugs work by drawing upon this disease-centred model, those drugs are 
sometimes presented as working in a way that is broadly analogous to how insulin works 
in diabetes. For example, in a manner somewhat similar to how insulin alleviates the 
symptoms associated with diabetes by compensating for the body’s inability to produce 
sufficient quantities of that hormone, psychiatric drugs are presented as alleviating or 
even eliminating the symptoms associated with mental distress by targeting and 
correcting the biological dysfunctions that are commonly presented as being implicated in 
such distress. In highlighting this supposedly selective character of psychiatric drugs, 
particularly those that emerged during the 1950s and that are said to have revolutionised 
the treatment of mental distress, Lieberman (2016) has proposed that ‘What made 
chlorpromazine, imipramine, and lithium so different from the sedatives and tranquilizers 
that came before was that they directly targeted psychiatric symptoms in a kind of 
lock-and-key relationship’ (p. 188).  
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The biological dysfunction that is most commonly presented as being implicated in 
mental distress, a dysfunction which psychiatric drugs are thought to target and correct, 
are chemical imbalances in the brain. Indeed, the way in which psychiatric drugs exert an 
influence on the action of a variety of neurotransmitters has been invoked as evidence for 
the claim that mental distress is a consequence of some form of chemical imbalance. For 
example, antipsychotic drugs have been found to block the action of the neurotransmitter 
dopamine and this has been used to formulate, and as evidence to support, the dopamine 
hypothesis of schizophrenia. While various versions of this hypothesis have been 
presented, in its most general sense it maintains that the experiences associated with a 
diagnosis of schizophrenia arise as a consequence of some form of imbalance, and in 
particular and over-stimulation, of the neurotransmitter dopamine (Howes and Kapur, 
2009). Similarly, many antidepressant drugs are understood to inhibit the reuptake of 
serotonin and noradrenaline, both classed as monoamine neurotransmitters, and this has 
been used to formulate, and as evidence to support, the monoamine hypothesis of 
depression. In particular, it has been suggested that the experiences associated with a 
diagnosis of depression are a manifestation of some form of imbalance, and in particular 
a deficiency, of either serotonin, noradrenaline or a combination of these two 
neurotransmitters (Hirschfeld, 2000; Mulinari, 2012). 
Despite its pervasiveness both within and beyond the field of mental health care, the 
claim that various chemical imbalances are implicated in mental distress, and that 
psychiatric drugs work by acting upon these imbalances, has been a matter of ongoing 
dispute. Such claims have been subject to sustained critical consideration from a variety 
of perspectives with detailed discussions of, for example, the social, economic and 
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political factors that have contributed to the emergence of this way of understanding 
mental distress and the drugs used to respond to that distress (Double, 2011; Lacasse and 
Leo, 2015; Whitaker, 2015). Arguably the most fundamental critique, however, is the 
suggestion that there is a lack of reliable, replicable and therefore compelling evidence 
that any form of biological dysfunction, including any form of chemical imbalance, 
underlies the emergence and maintenance of mental distress. With the exception of 
‘organic mental disorders’ or ‘organic brain syndromes’ such as Huntington’s disease, it 
has been suggested that a clear and convincing biological cause has not been 
demonstrated for the vast majority of ‘psychiatric disorders’ including schizophrenia, 
bipolar disorder and depression (Cromby et al., 2013; Deacon, 2013). Therefore, while it 
is common to encounter claims that mental distress is a consequence of some form of 
chemical imbalance, and that psychiatric drugs work by acting upon these imbalances, the 
evidence for such claims is said to be unconvincing, misleading or simply non-existent 
(Moncrieff, 2008; Gøtzsche, 2013; Lynch, 2015). 
To propose that there is no compelling evidence for the assertion that various forms 
of chemical imbalances are implicated in mental distress, imbalances that psychiatric 
drugs selectively target and address, may strike some as controversial. It seems intuitively 
correct to conclude that because psychiatric drugs can have beneficial effects on the 
various symptoms associated with mental distress, and because those drugs act on an 
individual’s neurochemisty in certain ways, then those symptoms must have been the 
result of some form of dysfunction or imbalance in that neurochemistry. However, while 
such an argument appears intuitively plausible, the form of thinking that it involves (what 
is referred to as ex juvantibus reasoning) is insufficient by itself to establish that the 
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symptoms associated with mental distress are a consequence of a neurochemical 
dysfunction. There are many instances in which drugs can produce beneficial effects 
upon the symptoms associated with a variety of conditions, and do so by modifying an 
individual’s biological systems in particular ways, and yet those systems play no part in 
the emergence of those conditions (Busfield, 2011). For example, aspirin and paracetamol 
can alleviate the symptoms associated with a variety of conditions including influenza 
and migraines; however, the fact that they achieve these effects by modifying biological 
systems in particular ways does not mean that such conditions are caused by dysfunctions 
or imbalances in the systems upon which aspirin and paracetamol act (Rose, 2006).  
The reasons why psychiatric drugs have come to be understood as precise 
medications that address various forms of chemical imbalance, despite a lack of 
compelling evidence for such an understanding, is complex and contested. Indeed, the 
reasons why any one particular approach to mental distress proliferates within and 
beyond the mental health field cannot simply be attributed to a supposed theoretical and 
therapeutic superiority over other approaches to mental distress. In any sphere of human 
inquiry a range of social, political and historical factors contribute to the establishment, 
maintenance and dominance of certain ways of understanding and responding to human 
experience while simultaneously delegitimising and excluding alternative ways of 
understanding and responding to that experience (Foucault, 1981). In mental health care, 
for example, it has been suggested that the pharmaceutical industry, driven by a financial 
imperative to maximise profits, has relentlessly employed various marketing strategies to 
promote chemical imbalance theories of mental distress and the effectiveness of 
psychiatric drugs to address those imbalances (Whitaker and Cosgrove, 2015). Moreover, 
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the proliferation of such claims has been attributed to the way in which they provide a 
seductively accessible account of how to understand mental distress which has therefore 
been readily perpetuated throughout society by the mass media (Boyle, 2015). In addition, 
it has been proposed that such claims are politically expedient in so far as they divert 
attention away from a consideration of the wider social and material conditions that can 
contribute to mental distress as well as the more financially and politically demanding 
task of attempting to address those conditions (Boyle, 2011). 
One of the most challenging proposals, however, is that mental health professionals 
have been instrumental in perpetuating the notion that mental distress is a manifestation 
of a neurochemical dysfunction that psychiatric drugs are able to correct. The reasons for 
doing so have variously been attributed to an unfamiliarity with the available research on 
psychiatric drugs, to deficiencies in the education and training of mental health 
professionals and to a desire on the part of practitioners to be perceived as possessing 
treatments that are analogous to those used in other branches of medicine (Moncrieff, 
2015). However, one of the most disturbing suggestions is that practitioners have actively 
employed chemical imbalance theories of mental distress as ‘productive metaphors’ in 
order to achieve a range of clinical objectives (Lacasse and Leo 2015). In doing so, it has 
been proposed that such explanations have been used to provide people with an 
accessible account of the complex, confusing and sometimes disturbing experiences that 
can be associated with mental distress. In addition, claims about the precise and targeted 
character of psychiatric drugs are said to have been used to reassure people that 
practitioners, when they prescribe and administer those drugs, have a sophisticated 
understanding of how they work. Moreover, there are even suggestions that health care 
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professionals have perpetuated notions that psychiatric drugs address the chemical 
imbalances of which mental distress is a supposed manifestation in order to facilitate 
compliance with psychiatric drugs as a response to that distress (Lacasse and Leo, 2015).   
The drug-centred model of psychiatric drugs
In so far as the disease-centred model of psychiatric drugs has been subject to sustained 
criticism from a variety of perspectives, an alternative pharmacological model has been 
proposed by which to understand the action of those drugs. This alternative understanding 
of how psychiatric drugs work, what Joanna Moncrieff (2015) has referred as ‘the 
drug-centred model’, maintains that those drugs do not correct some form of chemical 
imbalance that supposedly underlies mental distress. Rather, this drug-centred model 
proposes that psychiatric drugs are powerful psychoactive substances that act upon the 
central nervous system to produce various alterations in a person’s thoughts, feelings and 
behaviour. While the disease-centred understanding of psychiatric drugs has been 
illustrated by drawing an analogy with the use of insulin in diabetes, the drug-centred 
understanding has been illustrated by drawing an analogy with the way in which some 
people use moderate amounts of alcohol to alleviate certain physiological and 
psychological experiences associated with social anxiety (Moncrieff, 2008). The use of 
alcohol in such instances is not understood in terms of the disease-centred 
pharmacological model as somehow targeting and correcting a chemical imbalance that 
supposedly underlies social anxiety. Rather, alcohol is understood in a drug-centred way 
as acting upon the central nervous system to produce an altered state and a range of 
physiological and psychological effects, effects which some people can find beneficial in 
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helping them deal with the varied experiences associated with social anxiety. 
Rather than being precise medications that selectively target and correct some form 
of neurochemical dysfunction, the drug-centred model therefore maintains that 
psychiatric drugs are imprecise substances or ‘blunt instruments’. In particular, this way 
of understanding psychiatric drugs proposes that they are powerful psychoactive 
substances that act upon the central nervous system in a non-specific rather than a precise 
manner and that by doing so they change or ‘perturb’ normal neurotransmitter function to 
produce a range of altered mental and physical states (Hyman and Nestler, 1996; 
Whitaker, 2015). Accordingly, while the disease-centred model suggests that psychiatric 
drugs work by returning supposedly imbalanced, dysfunctional and abnormal brain states 
back to normal, the drug-centred model maintains that psychiatric drugs produce 
abnormal, artificial or intoxicated brain states by disrupting normal neurotransmitter 
function (Breggin, 2006; Moncrieff, 2015). In doing so, each psychiatric drug is 
understood as producing its own distinctive drug-induced state that has a variety of 
physiological and psychological effects, effects that may be experienced by some people 
as being helpful in dealing with the various experiences that can be associated with 
mental distress. In illustrating this alternative drug-centred understanding of psychiatric 
drugs, and how the altered states that those drugs produce may be experienced by some 
people as beneficial, Moncrieff (2013) makes it clear that ‘The drug-centred model 
suggests that drugs can sometimes be helpful because the features of the altered 
drug-induced state superimpose themselves onto the manifestations of distress’ (p. 161).
In further understanding how the drug-centred model accounts for the way in which 
psychiatric drugs can produce effects that some people may find beneficial, it is 
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productive to consider that model within the context of antipsychotic drugs. As a 
response to the experiences associated with a diagnosis of schizophrenia, antipsychotics 
are not to be understood as correcting some form of neurochemical imbalance such as an 
overstimulation of dopamine. Rather, by blocking the action of dopamine and affecting a 
range of other brain systems, the drug-centred model suggests that antipsychotics create a 
drug-induced state similar to Parkinson’s disease in which mental and physical activity is 
suppressed – a condition which has variously been referred to as a state of ‘deactivation’, 
‘immobilisation’ or ‘tranquilisation’ (Breggin, 1993; Moncrieff, 2008; Healey, 2016). 
However, this tranquilised state is not to be thought of as being comparable to a condition 
of relaxation and neither should it be thought of as a ‘chemical cosh or straightjacket’ - 
although antipsychotics can produce a state of immobilised sedation if used in high 
enough doses. Instead, antipsychotics are said to produce a state of indifference or 
detachment, a ‘who cares feeling’ that some may find beneficial for the so-called 
‘positive symptoms’ of schizophrenia by suppressing, or making people less responsive 
to, the presence of hallucinations, delusions and the anxiety that can accompany them 
(Mizrahi et al., 2005; Kapur et al., 2006).
Rather than being a chemical cure that removes the distressing experiences 
associated with schizophrenia, the drug-centred model therefore maintains that 
antipsychotics produce an altered state in which people can become less concerned by 
those experiences. However, although some people may find antipsychotic drugs 
beneficial in this way, it is important to recognise that the general suppression of mental 
and physical activity that they produce does not selectively target particular experiences 
associated with schizophrenia (Barnes, 2011). That is, while creating a distinctive state of 
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detachment or indifference, antipsychotics do not simply create a sense of indifference 
towards the experiences associated with a diagnosis of schizophrenia but can instead 
create a sense of indifference towards all experiences. For example, those who use 
antipsychotics report that the full range of human emotions can not only come to be 
experienced with less intensity, but there can be an emotional ‘flattening’ or ‘blunting’ 
that is characterised by a lack or absence of emotion (Moncrieff et al., 2015; Healey, 
2016). Similarly, the generalised suppression of mental and physical activity that 
antipsychotics produce can not only impair a person’s attention, memory and general 
thought processes, but it can also reduce their motivation to initiate actions, carry out 
simple tasks and engage with others. Indeed, such effects can present as being similar to 
the so-called ‘negative symptoms’ of schizophrenia (which include apathy, social 
withdrawal and reduced motivation) and both typical and atypical antipsychotics have 
been found to show limited benefit for the treatment of these symptoms (Erhart et al., 
2006; Lewis and Lieberman, 2008). 
While the drug-centred model illustrates how psychiatric drugs can produce a range 
of physiological and psychological effects that some people may find beneficial, it 
therefore also helps to understand how those drugs can produce a range of undesirable, 
adverse effects. As powerful psychoactive substances that act upon the central nervous 
system to alter normal functioning in a non-specific rather than a targeted way, 
psychiatric drugs (in a manner analogous to alcohol) can produce a range of effects that 
can not only be unpleasant and unhelpful but can also be experienced as intolerable 
(Correll et al., 2015). However, while psychiatric drugs can produce a variety of adverse 
effects, it has been suggested that mental health professionals may be unaware of the full 
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range of those effects, minimise their significance for the person taking the drug or 
misinterpret such effects as a deterioration in a person’s mental health rather than as 
adverse reactions caused by a psychiatric drug (Breggin, 2006; Read, 2009). Indeed, it 
has been proposed that there can be a tendency in mental health settings to attribute a 
deterioration in a person’s well-being to a relapse or worsening of their ‘underlying 
mental disorder’ rather than an adverse effect produced by a psychiatric drug; as a 
consequence, there can be a demand to respond to such a perceived deterioration or 
relapse by increasing the dosages of psychiatric drugs which, in turn, can increase the 
risks of adverse drug reactions (Healey, 2016).   
In order to provide informed, safe and effective mental health care that is responsive 
to the needs of people who use mental health services, it has been suggested that 
practitioners should develop their ability to recognise the range of adverse effects, both 
short-term and long-term, that psychiatric drugs can produce (Healey, 2016). Doing so, 
however, can be a considerable challenge. The briefest of investigations will reveal that 
psychiatric drugs can produce an extensive and alarming range of adverse effects. These 
will not only include predictable effects that are caused by the drugs normal 
pharmacological activity, such as the extrapyramidal effects associated with 
antipsychotics or the risk of toxicity associated with lithium. Rather, psychiatric drugs 
can produce a range of idiosyncratic, unpredictable effects that result from processes not 
yet fully understood and that may go largely unrecognised, such as the serotonin 
syndrome associated with antidepressants and selective serotonin reuptake inhibitors in 
particular (Ellahi, 2015). To facilitate the reporting and recognition of the range of 
adverse effects that can be produced by psychiatric drugs, it has therefore been suggested 
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that it is necessary to create a clinical climate in which those taking such drugs feel able 
to report potential adverse drug reactions (Healey, 2016). Central to achieving this is a 
willingness on the part of practitioners to remain open-minded about the possibility that 
any problems reported, even those that are not generally considered to be established or 
predictable adverse effects, may be a consequence of taking a psychiatric drug.     
Psychiatric drug models and service user involvement    
The enduring influence of the disease-centred understanding of psychiatric drugs has 
far-reaching implications for those who use mental health services and for how those 
drugs are used as a response to mental distress. In so far as psychiatric drugs have been 
understood as precise medications that target and correct some form of chemical 
imbalance or biological dysfunction, then decisions about those drugs (such as dose, 
duration and discontinuation) have largely come to be seen as technical matters that are 
determined by mental health professionals. As a consequence, the experiences and 
opinions of those who are prescribed and take psychiatric drugs can become subordinated 
to the specialist knowledge and judgements of practitioners. While there is an emerging 
interest in equitable, shared decision-making between mental health professionals and 
those who use mental health services, it has been suggested that the meaningful 
involvement of service users in decisions about psychiatric drugs remains, in practice, 
limited (Matthias et al., 2012; Kaminskiy et al., 2013; Morant et al., 2016). Indeed, the 
relationship between mental health professionals and those who use psychiatric drugs can 
become predominately centred around the issue of ‘medication adherence’. By 
maintaining assumptions about the selective and corrective character of psychiatric drugs, 
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practitioners can become almost exclusively focused on seeking to ensure that people 
experiencing mental distress adhere to the drug regimens that have been formulated for 
them (Deegan and Drake, 2006).   
By maintaining assumptions about the precise and targeted character of psychiatric 
drugs to address some form of supposed neurochemical dysfunction, there can a tendency 
to use a range of strategies to ensure medication compliance (Mitchell and Selmes, 2007; 
Chapman and Horne, 2013). While recommendations are often made that compliance 
should occur in the context of a therapeutic alliance, it has been claimed that there are 
instances in which it is secured through the use of various forms of coercion such as 
‘subtle persuasion’, ‘strategic dishonesty’ and compulsory enforcement of drug treatment 
(Seale et al., 2006; Chaplin, 2007). Moreover, in an attempt to ensure medication 
adherence, the adverse effects of psychiatric drugs can be given minimal consideration by 
mental health professionals. For example, when adverse effects are reported by those 
using psychiatric drugs, it has been suggested that some practitioners contest, disbelieve 
or disregard those reports (Seale et al., 2007; Read, 2009). In so far as psychiatric drugs 
are understood as precise medications that selectively correct some form of chemical 
imbalance, then consideration of the adverse effects of those drugs can become 
subordinated to a powerful assumption about the short-term and long-term effectiveness 
of those drugs. Indeed, such an assumption can be understood as finding its expression in 
the description of any adverse consequence of taking a psychiatric drug as a ‘side’ effect 
that, while potentially ‘unpleasant’, is seen as a tolerable by-product of that drug’s 
supposedly beneficial ‘main’ effect of addressing the dysfunctions that are thought to 
underlie mental distress (Moncrieff and Cohen, 2009). 
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In contrast to the disease-centred model of psychiatric drugs, and the manner in 
which it can contribute to the marginalisation of the experiences of people who take those 
drugs, the drug-centred model implies a more equitable or democratic relationship 
between practitioners and mental health service users. Understanding psychiatric drugs  
as powerful psychoactive substances that act in a non-specific way to produce a range of 
physiological and psychological effects, the drug-centred model places fundamental 
importance on the experiences of the person taking a psychiatric drug. Rather than being 
subordinated to the knowledge and judgements of practitioners, it is the individual 
experience of the service user that is given priority when deciding whether the range of 
effects that can be produced by a psychiatric drug are beneficial for the symptoms that 
comprise that individual’s experience of mental distress. Moreover, against understanding 
any adverse effect as a tolerable by-product of a drug’s supposedly beneficial main effect, 
the drug-centred model implies that all of the effects produced by a psychiatric drug 
should be taken into account when deciding upon its effectiveness. In doing so, there is 
an acknowledgement that while some effects may be experienced by one person as 
beneficial (such as the manner in which the tranquilising effects of antipsychoitcs may 
help some people cope with the positive symptoms of schizophrenia) the same or similar 
effects might be experienced by another person as undesirable, unhelpful and even 
disabling.  
Against the attempt to ensure compliance with a drug-treatment regimen that has 
been exclusively formulated by mental health professionals, the drug-centred model 
suggests that decisions about whether a psychiatric drug may be helpful or not is an open, 
dynamic and collaborative process. In particular, both the mental health service user and 
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the practitioner draw upon their respective expertise and experience to investigate which 
effects induced by a psychiatric drug may, and may not, be beneficial. In doing so, there 
is a recognition of the actual and potential adverse effects of taking a psychiatric drug, 
both in the short-term and the long-term, such that the decision about whether a drug is 
helpful or not becomes an ongoing collaborative attempt to balance the actual and 
potential benefits of a drug against the adverse effects that it may produce. A variety of 
potential obstacles can be associated with the attempt to establish such equitable 
relationships, not least the challenge of how to address the imbalances in power, 
influence and status that exist between those who use and those who provide mental 
health services (Beresford, 2013; Faulkner et al., 2015). However, understanding 
psychiatric drugs as powerful, non-selective psychoactive substances not only places a 
demand on practitioners to develop a more sophisticated understanding of the range of 
effects that those drugs can produce. Rather, it also prioritises the need to productively 
engage with service users as legitimate partners in determining the effectiveness of 
psychiatric drugs as a response to their experience of mental distress.   
By emphasising the centrality of the individual experience of taking a psychiatric 
drug, and the ongoing need to balance the drug-induced effects that a person may find 
helpful against those effects which they do not, the drug-centred model provides a 
rationale for what has variously been referred to as the ‘periodic’, ‘strategic’ or ‘flexible’ 
use of psychiatric drugs (Moncrieff and Cohen 2009; Healey, 2016). In doing so, there is 
a recognition that the continuous, long-term use of psychiatric drugs can produce effects 
that may inhibit, rather than facilitate, an individual’s recovery from mental distress 
(Double, 2011; Wunderink et al., 2013; Gøtzsche et al., 2015). Therefore, a more 
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effective way to use those drugs may be to employ them when they are needed, such as in 
response to a deterioration in a person’s mental health or to help a person cope with 
challenging life events. Indeed, there is evidence to suggest that some people already use 
psychiatric drugs in this flexible or strategic way by increasing, decreasing or omitting 
doses in response to variations in the symptoms that comprise their experience of mental 
distress (Deegan and Drake 2006; Britten et al., 2010). In the context of an increased 
sensitivity to the potentially harmful effects of the long-term use of psychiatric drugs, 
their strategic employment is therefore not only concerned with alleviating the symptoms 
of mental distress. Rather, it is also simultaneously concerned with ensuring the need to 
maximise a person’s long-term physiological, psychological and social functioning. 
With its emphasis on the flexible and periodic use of psychiatric drugs, the 
drug-centred model therefore not only recognises the role that those drugs can have in 
helping people deal with the experiences associated with mental distress but it also 
highlights their limitations. Rather than being precise medications that target and correct 
a supposed biological dysfunction while leaving the rest of the body undisturbed, the 
drug-centred model maintains that psychiatric drugs are imprecise or blunt instruments. 
While they can produce effects that some people might find helpful, they also produce 
short-term and long-term effects that others may find unhelpful, unpleasant and even 
intolerable. As such, there might be some who conclude that the experiences associated 
with mental distress are less disruptive to their lives than the adverse effects produced by 
the drugs that are used to treat such distress. In the context of the drug-centred 
understanding of psychiatric drugs, such a decision should not be understood as evidence 
that a person ‘lacks insight’ or that their mental health is deteriorating for which more 
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aggressive drug-treatment is required. Moreover, it should not simply be assumed that 
people who experience mental distress do not possess, or are unable to develop, the 
resilience and strategies to cope without psychiatric drugs (Deegan, 2005). Rather, there 
should be an acknowledgement that alternative non-pharmacological means do exist and 
practitioners ought to provide the information, support and opportunity for people to 
explore such means alongside, or even as an alternative to, the use of psychiatric drugs. 
Conclusion 
Assumptions about the way in which psychiatric drugs are thought to work have 
important implications for those who use mental health services. While such assumptions 
may be infrequently articulated they can influence the way in which those drugs are used, 
the manner in which their potential benefits are balanced against their adverse effects and 
the extent to which those who use psychiatric drugs are meaningfully involved in 
decisions about their use. In the context of the widespread and enduring disease-centred 
model of psychiatric drugs, those drugs are commonly understood as selective agents that 
address the various forms of biological dysfunction that supposedly underlie the 
emergence and maintenance of mental distress. As such, there can be a tendency to view 
psychiatric drugs as predominately being a technical matter in which decisions about their 
use are largely determined by the specialist knowledge and judgements of practitioners. 
As a consequence of sustained criticism of the disease-centred model of psychiatric drugs, 
an alternative pharmacological model has been proposed by which to understand the 
mode of action of those drugs. In the context of this alternative drug-centred model, 
psychiatric drugs are understood as powerful psychoactive substances that act upon the 
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central nervous system in a non-specific rather than a targeted way to produce a range of 
physiological and psychological effects. As such, this model places increased importance 
on investigating which of these effects a person may helpful and which they do not and, 
in doing so, implies that decisions about psychiatric drugs should occur within the context 
of an op n, dynamic and collaborative relationship with those who use mental health 
services.    
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